Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 and adebrelimab in advanced non-squamous NSCLC
NCT07464327Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 3 trial of risvutatug rezetecan in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07464327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07464327.